Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Matsuda, Yasufumi, Yamauchi, Takahiro, Hosono, Naoko, Uzui, Kanako, Negoro, Eiju, Morinaga, Koji, Nishi, Rie, Yoshida, Akira, Kimura, Shinya, Maekawa, Taira, Ueda, Takanori
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://ncbi.nlm.nih.gov/pubmed/27166836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12965
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars